The US FDA has not yet found an association between oral bisphosphonates and the risk of atypical subtrochanteric femur fractures,

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2010年 / 1293卷 / 1期
关键词：
Public Health; Clinical Trial; Osteoporosis; Bisphosphonates; Healthcare Professional;
D O I：
10.2165/00128415-201012930-00004
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2 / 2
相关论文
共 31 条
  • [21] Risk of atypical femoral fractures and osteonecrosis of the jaw associated with alendronate use compared with other oral bisphosphonates
    Kharazmi, Mohammad
    Hallberg, Par
    Warfvinge, Gunnar
    Michaelsson, Karl
    RHEUMATOLOGY, 2014, 53 (10) : 1911 - 1913
  • [22] The association between adherence with oral bisphosphonates and the risk of breast cancer in post-menopausal women
    Rouach, Vanessa
    Goldshtein, Inbal
    Buch, Assaf
    Catane, Raphael
    Chodick, Gabriel
    Stern, Naftali
    Shalev, Varda
    Cohen, Daniel
    JOURNAL OF BONE ONCOLOGY, 2019, 16 : 1 - 7
  • [23] The association of race/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy
    Lo, Joan C.
    Hui, Rita L.
    Grimsrud, Christopher D.
    Chandra, Malini
    Neugebauer, Romain S.
    Gonzalez, Joel R.
    Budayr, Amer
    Lau, Gene
    Ettinger, Bruce
    BONE, 2016, 85 : 142 - 147
  • [24] FDA reviews data regarding association between oral bisphosphonate therapy and esophageal cancer risk
    不详
    FORMULARY, 2011, 46 (09) : 373 - 373
  • [25] Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases
    Pazianas, M.
    Abrahamsen, B.
    Wang, Y.
    Russell, R. G. G.
    OSTEOPOROSIS INTERNATIONAL, 2012, 23 (12) : 2873 - 2884
  • [26] Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases
    M. Pazianas
    B. Abrahamsen
    Y. Wang
    R. G. G. Russell
    Osteoporosis International, 2012, 23 : 2873 - 2884
  • [27] A study by US researchers has found that while short-term oral contraceptive use may not be associated with the risk of breast cancer
    Reactions Weekly, 2007, 1150 (1) : 5 - 5
  • [28] Risk association between estrogen containing oral contraceptives/hormonal therapy and pregnancy on atypical venous thromboembolism
    Kalsi, H.
    McBane, R.
    Wysokinski, W.
    THROMBOSIS RESEARCH, 2007, 119 : S107 - S108
  • [29] The US FDA has issued an Early Communication of its ongoing safety review about association between bisphosphonate use and atrial fibrillation (AF)
    Reactions Weekly, 2007, 1172 (1) : 3 - 3
  • [30] THE ASSOCIATION BETWEEN CALCIUM ±VITAMIN D SUPPLEMENTATION AND FRACTURE RISK AMONG INCIDENT USERS OF ORAL BISPHOSPHONATES: A POPULATION-BASED COHORT STUDY
    Reyes, C.
    Hawley, S.
    Javaid, M. K.
    Diez-Perez, A.
    Cooper, C.
    Prieto-Alhambra, D.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 : S305 - S305
1234